162 related articles for article (PubMed ID: 20357034)
1. Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.
Chuang E; Wiener N; Christos P; Kessler R; Cobham M; Donovan D; Goldberg GL; Caputo T; Doyle A; Vahdat L; Sparano JA
Ann Oncol; 2010 Oct; 21(10):2075-2080. PubMed ID: 20357034
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
5. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.
Floquet A; Doussau A; Brouste V; Cany L; Dutin JP; Mathoulin-Pélissier S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):61-8. PubMed ID: 24141374
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Koinis F; Polyzos A; Christopoulou A; Zafeiriou Z; Emmanouilidis C; Papadimitraki E; Kalykaki A; Kalbakis K; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2014 Apr; 73(4):819-25. PubMed ID: 24531559
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM
Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626
[TBL] [Abstract][Full Text] [Related]
9. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.
Iqbal S; Tsao-Wei DD; Quinn DI; Gitlitz BJ; Groshen S; Aparicio A; Lenz HJ; El-Khoueiry A; Pinski J; Garcia AA
Am J Clin Oncol; 2011 Feb; 34(1):27-31. PubMed ID: 20142723
[TBL] [Abstract][Full Text] [Related]
11. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
13. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Vahdat LT; Vrdoljak E; Gómez H; Li RK; Bosserman L; Sparano JA; Baselga J; Mukhopadhyay P; Valero V
J Geriatr Oncol; 2013 Oct; 4(4):346-52. PubMed ID: 24472478
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.
Simpkins F; Flores A; Chu C; Berek JS; Lucci J; Murray S; Bauman J; Struemper H; Germaschewski F; Jonak Z; Gardner O; Toso J; Coukos G
Cancer Immunol Res; 2013 Sep; 1(3):168-78. PubMed ID: 24777679
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG
Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267
[TBL] [Abstract][Full Text] [Related]
18. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
Del Conte G; Sessa C; von Moos R; Viganò L; Digena T; Locatelli A; Gallerani E; Fasolo A; Tessari A; Cathomas R; Gianni L
Br J Cancer; 2014 Aug; 111(4):651-9. PubMed ID: 25025963
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]